电邮这篇文章 SPECIFIC MECHANISMS OF THROMBOSIS FORMATION AT PH-NEGATIVE MYELOPROLIFERATIVE NEW FORMATIONS
- 作者: Serbin A.N1
-
隶属关系:
- S.M. Kirov Military Medical Academy of the Ministry of Defense
- 期: 卷 39, 编号 1-1S (2020)
- 页面: 151-154
- 栏目: Articles
- URL: https://journals.rcsi.science/RMMArep/article/view/43397
- DOI: https://doi.org/10.17816/rmmar43397
- ID: 43397
如何引用文章
全文:
详细
The most relevant Ph-negative myeloproliferative neoplasms (MPN) include: polycythemia vera (PI), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Thrombosis and thromboembolism currently remain the main cause of disability and mortality in MPN. Most modern methods of specific cytoreductive therapy for MPN do not significantly affect the incidence of thrombotic complications, and in some cases may even contribute to their development. Therefore, the use of antithrombotic, primarily antiplatelet, therapy remains the most effective direction of prevention. Currently, various anticoagulants are becoming more common. For their introduction into hematological practice, a clear understanding of the formation of specific mechanisms of pathological thrombosis in MPN is necessary. To this end, we analyzed the disease-specific pathogenetic mechanisms of "thrombophilia" in various Ph-negative MPN.
作者简介
A. Serbin
S.M. Kirov Military Medical Academy of the Ministry of DefenseSt. Petersburg, Russia
参考
- Меликян, А.Л. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний / А.Л. Меликян, А.Г. Туркина, К.М. Абдулкадыров [и др.] // Гематология и трансфузиология. - 2014. - №4(59). - С.31-56.
- Поляков, А.С. Новые подходы к терапии классических Ph-негативных миелопролиферативных новообразований: опыт раннего при-менения цепэгинтерферона альфа А-2B / А.С. Поляков, Я.А. Носков, В.В. Тыренко [и др.] // Онкогематология. - 2018. - №1(13). - С.29-44.
- Диагностика и лечение Ph-негативных миелопролиферативных новообразований в Военно-медицинской академии имени С.М. Кирова: Методические рекомендации и локальный протокол лечения / Под ред. В.В. Тыренко. - СПб.: ВМедА, 2019. - 84 с.
- Borowczyk, M. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in pa-tients with Philadelphia-negative myeloproliferative neoplasms / M. Borowczyk, M. Wojtaszewska, K. Lewandowski [et al.] // Thrombosis Re-search. - 2015. - №135(2). - С.272-280.
- Guadall, A. Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features / A. Guadall, E. Lesteven, G. Letort [et al.] // Thromb. Haemost. - 2018. - №118(9). - С.1586-1589.
- Guy, A. La thrombose au cours des ne oplasies mye loprolife ratives / A. Guy, C. James // Me decine/sciences. - 2019. - №35(8-9). - С.651-658.
- Tong, D. Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients / D. Tong, M. Yu, L. Guo [et al.] // Ann. Hematol. - 2018. - №97(4). - С.605-616.
- Vannucchi, A.M. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden / A.M. Vannucchi, P. Guglielmelli, G. Longo [et al.] // Leukemia. - 2007. - №21(9). - С.1952-1959.
补充文件
